In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue

Journal of Cellular Biochemistry

Volumn 91, Issue 1, 2004, Pages 196-205

  Uzgare, Aarti R ^a   Xu, Yi ^a   Isaacs, John T ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Basal cells; Normal prostate; PrEC; Prostate cancer; Stem cells; Transit amplifying cells

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; ANDROGEN;

ADENOCARCINOMA; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; PROGENY; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE EPITHELIUM; REVIEW; SECRETORY CELL; STEM CELL; ARTICLE; CELL AGING; CELL DIVISION; CELL LINEAGE; CELL TRANSFORMATION; CHEMISTRY; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECT; EPITHELIUM CELL; MALE; METABOLISM; PHYSIOLOGY; PROSTATE;

ANDROGENS; CELL AGING; CELL DIFFERENTIATION; CELL DIVISION; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CULTURE MEDIA, SERUM-FREE; EPITHELIAL CELLS; HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; STEM CELLS;

EID: 3242743136     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.10764     Document Type: Review

References (43)

1. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT. 1995. Implication of the cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1:473-480.
2. Bhatt RI, Brown MD, Hart CA, Gilmore P, Ramani VAC, George NJ, Clarke NW. 2003. Novel method for the isolation and characterization of the putative prostatic stem cell. Cytometry Part A 54A:89-99.
3. Bonkhoff H, Remberger K. 1996. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth-a stem cell model. Prostate 28:98-106.
4. Bonkhoff H, Stein U, Remberger K. 1994. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: Simultaneous demonstration of cell-specific epthelial markers. Hum Pathol 25:42-46.
5. Bonkhoff H, Stein U, Remberger K. 1994. The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 24:114-118.
6. Bonkhoff H, Fixemer T, Remberger K. 1998. Relation between Bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate 34:251-258.
7. Chopra DP, Grignon DJ, Joiakim A, Mathieu PA, Mohamed A, Sakr WA, Powell IJ, Sarkar FH. 1996. Differential growth factor responses of epithelial cell cultures derived from normal human prostate, benign prostatic hyperplasia, and primary prostate carcinoma. J Cell Physiol 169: 269-280.
8. 1-integrin expression. J Cell Sci 114:3865-3872.
9. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y. 1987. The endocrinology and developmental biology of the prostate. Endocr Rev 8: 338-362.
10. De Marzo AM, Meeker AK, Epstein JI, Coffey DS. 1998a. Prostate stem cell compartments: Expression of the cell cycle inhibitor p27kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol 153:911-919.
11. De Marzo AM, Nelson WG, Meeker AK, Coffey DS. 1998b. Stem cell features of benign and malignant prostate epithelial cells. J Urol 160:2381-2392.
12. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. 1999. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 155:1985-1992.
13. Denmeade SR, Lin XS, Isaacs JT. 1996. Role of programmed (apoptotic) cell death during the progression and therapy of prostate cancer. Prostate 28:251-265.
14. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT. 2003a. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 54:249-257.
15. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB, Isaacs JT. 2003b. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 95:990-1000.
16. Gao J, Arnold JT, Isaacs JT. 2001. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 61:5038-5044.
17. Garraway LA, Lin D, Signoretti S, Waltregny D, Dilks J, Bhattacharya N, Loda M. 2003. Intermediate basal cells of the prostate: In vitro and in vivo characterization. Prostate 55:206-218.
18. Hayward SW, Del Buono R, Deshpande N, Hall PA. 1992. A functional model of adult human prostate epithelium: The role of androgens and stroma in architectural organization and the maintenance of differentiated secretory function. J Cell Sci 102:361-372.
19. Hayward SW, Haughney PC, Lopes ES, Danielpour D, Cunha GR. 1999. The rat prostatic epithelial cell line NRP-152 can differentiate in vivo in response to its stromal environment. Prostate 39:205-212.
20. Hudson DL, O'Hare M, Watt FM, Master JR. 2000. Proliferative heterogeneity in the human prostate: Evidence for epithelial stem cells. Lab Invest 80:1243-1250.
21. Isaacs JT. 1984. Antagonistic effect of androgen on prostatic cell death. Prostate 5:545-557.
22. Isaacs JT. 1987. Control of cell proliferation and cell death in the normal and neoplastic prostate: A stem cell model. In: Rogers CH, Coffey DS, Cunha G, Grayhack J, Hinman F, Horton R, editors. Benign prostatic hyperplasia. Report No. INH 87-2881. Bethesda, MD: Department of Health and Human Services, National Institutes of Health. pp 85-94.
23. Isaacs JT, Coffey DS. 1989. Etiology of BPH. Prostate Suppl 2:33-58.
24. Kurita T, Wany YZ, Donjacour AA, Zhao C, Lydon JP, O'Malley BW, Isaacs JT, Dahiya R, Cunha GR. 2001. Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 8:192-200.
25. Kyprianou N, Isaacs JT. 1987. Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: Critical threshold concept. Prostate 11:41-50.
26. Kyprianou N, Isaacs JT. 1988. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122:552-562.
27. Kyprianou N, Isaacs JT. 1989. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 3:1515-1522.
28. Lajtha LG. 1979. Stem cell concepts. Differentiation 14: 23-24.
29. Litvinov IV, De Marzo AM, Isaacs JT. 2003. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 88:2972-2982.
30. Liu AY, Peehl DM. 2001. Characterization of cultured human prostatic epithelial cells by cluster designation antigen expression. Cell Tissue Res 305:389-397.
31. Lu W, Luo Y, Kan M, McKeehan WL. 1999. Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem 274:12827-12834.
32. 1 on proliferation and death of rat prostatic cells. Endocrinology 127:2963-2968.
33. McNeal JE, Bostwick DG. 1986. Intraductal dysplasia: A premalignant lesion of the prostate. Hum Pathol 17:64-71.
34. Meeker AK, Hicks JL, Platz EA, March GE, Bennett CJ, Delannoy MJ, DeMarzo AM. 2002. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res 62:6406-6409.
35. Planz B, Aretz HT, Wang Q, Tabatabaei S, Kirley SD, Lin CW, McDougal WS. 1999. Immunolocalization of the keratinocyte growth factor in benign and neoplastic human prostate and is relation to androgen receptor. Prostate 41:233-242.
36. Potten CS, Lajtha LG. 1982. Stem cells versus stem lines. Ann NY Acad Sci 397:49-61.
37. Robinson EJ, Neal DE, Collins AT. 1998. Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostate epithelium. Prostate 37:149-160.
38. Rumpold H, Heinrich E, Untergasser G, Hermann M, Pfister G, Plas E, Berger P. 2002. Neuroendocrine differentiation of human prostatic primary epithelial cells in vitro. Prostate 53:101-108.
39. Tran CP, Lin C, Yamashiro J, Reiter RE. 2002. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Molec Can Res 1: 113-121.
40. van Leenders GJLH, Schalken JA. 2003. Epithelial cell differentiation in the human prostate epithelium: Implications for the pathogenesis and therapy of prostate cancer. Oncol Hemat 46:S3-S10.
41. van Leenders G, Dijkman H, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. 2000. Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab Invest 80:1251-1258.
42. van Leenders G, van Balken B, Aalders T, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. 2002. Intermediate cells in normal and malignant prostate epithelium express c-MET: Implications for prostate cancer invasion. Prostate 51:98-107.
43. Verhagen AP, Ramaekers FC, Aalders TW, Schaafsma HE, Debruyne FM, Schalken JA. 1992. Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res 52:6182-6187.